NURIX THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
NURIX THERAPEUTICS, INC. (NRIX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $2.77 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-05-31 was $45.00K, a 99.83% decline year-over-year.
- NURIX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-02-28 was $2.72M.
- NURIX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-11-30 was $0.00, a 100.00% decline year-over-year.
- NURIX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-08-31 was $5.79M.
- NURIX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $32.49M, a 691.19% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $4.11M, a 82.88% decline from fiscal 2023.
- NURIX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $24.00M, a 373.46% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $5.07M, a 0.00% change from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2026-05-31 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $2.77M 10-Q · filed 2026-07-09 | $2.77M derived: sum of 3 quarters · filed 2026-07-09 | $8.55M derived: sum of 4 quarters · filed 2026-07-09 | |
| 2026-02-28 | $2.72M 10-Q · filed 2026-04-08 | $2.72M derived: sum of 2 quarters · filed 2026-04-08 | $8.51M derived: sum of 3 quarters · filed 2026-04-08 | $35.21M derived: sum of 4 quarters · filed 2026-07-09 | |
| 2025-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $5.79M derived: sum of 2 quarters · filed 2026-01-28 | $32.49M derived: sum of 3 quarters · filed 2026-07-09 | $32.49M 10-K · filed 2026-01-28 | |
| 2025-08-31 | $5.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $32.49M derived: sum of 2 quarters · filed 2026-07-09 | $32.49M 10-Q · filed 2025-10-09 | $35.30M derived: sum of 4 quarters · filed 2026-07-09 | |
| 2025-05-31 | $26.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $26.71M 10-Q · filed 2026-07-09 | $29.52M derived: sum of 3 quarters · filed 2026-07-09 | $29.52M derived: sum of 4 quarters · filed 2026-07-09 | |
| 2025-02-28 | $0.00 10-Q · filed 2026-04-08 | $2.81M derived: sum of 2 quarters · filed 2026-04-08 | $2.81M derived: sum of 3 quarters · filed 2026-04-08 | ||
| 2024-11-30 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $2.81M derived: sum of 2 quarters · filed 2026-01-28 | $4.11M 10-K · filed 2026-01-28 | ||
| 2024-08-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $1.30M 10-Q · filed 2025-10-09 | |||
| 2024-05-31 | $1.30M 10-Q · filed 2025-07-09 | ||||
| 2023-11-30 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $24.00M derived: sum of 2 quarters · filed 2026-01-28 | $24.00M derived: sum of 3 quarters · filed 2026-01-28 | $24.00M 10-K · filed 2026-01-28 | |
| 2023-08-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $0.00 derived: sum of 2 quarters · filed 2024-10-11 | $0.00 10-Q · filed 2024-10-11 | $8.00K derived: sum of 4 quarters · filed 2025-01-28 | |
| 2023-05-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $0.00 10-Q · filed 2024-07-11 | $8.00K derived: sum of 3 quarters · filed 2025-01-28 | $264.00K derived: sum of 4 quarters · filed 2025-01-28 | |
| 2023-02-28 | $0.00 10-Q · filed 2023-04-13 | $8.00K derived: sum of 2 quarters · filed 2025-01-28 | $264.00K derived: sum of 3 quarters · filed 2025-01-28 | $1.15M derived: sum of 4 quarters · filed 2025-01-28 | |
| 2022-11-30 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $264.00K derived: sum of 2 quarters · filed 2025-01-28 | $1.15M derived: sum of 3 quarters · filed 2025-01-28 | $5.07M 10-K · filed 2025-01-28 | |
| 2022-08-31 | $256.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $1.14M derived: sum of 2 quarters · filed 2023-10-12 | $5.06M 10-Q · filed 2023-10-12 | $8.03M derived: sum of 4 quarters · filed 2023-10-12 | |
| 2022-05-31 | $888.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $4.80M 10-Q · filed 2023-07-13 | $7.78M derived: sum of 3 quarters · filed 2023-07-13 | $7.78M derived: sum of 4 quarters · filed 2023-07-13 | |
| 2022-02-28 | $3.92M 10-Q · filed 2023-04-13 | $6.89M derived: sum of 2 quarters · filed 2023-04-13 | $6.89M derived: sum of 3 quarters · filed 2023-04-13 | ||
| 2021-11-30 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $2.97M derived: sum of 2 quarters · filed 2023-02-09 | $5.07M 10-K · filed 2023-02-09 | $2.37M 10-K · filed 2022-01-28 | |
| 2021-08-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $2.10M 10-Q · filed 2022-10-06 | |||
| 2021-05-31 | $2.10M 10-Q · filed 2022-07-07 | ||||
| 2020-11-30 | $2.37M 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |